Vilija G. Jokubaitis
Vilija G. Jokubaitis
Senior Research Fellow, Neuroimmunology Genomics and Prognostics Group Head, Monash University
Verified email at
Cited by
Cited by
Geographical variations in sex ratio trends over time in multiple sclerosis
M Trojano, G Lucchese, G Graziano, BV Taylor, S Simpson Jr, V Lepore, ...
PLOS one 7 (10), e48078, 2012
Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis
T Kalincik, D Horakova, T Spelman, V Jokubaitis, M Trojano, A Lugaresi, ...
Annals of neurology 77 (3), 425-435, 2015
Fingolimod after natalizumab and the risk of short-term relapse
VG Jokubaitis, V Li, T Kalincik, G Izquierdo, S Hodgkinson, R Alroughani, ...
Neurology 82 (14), 1204-1211, 2014
Defining secondary progressive multiple sclerosis
J Lorscheider, K Buzzard, V Jokubaitis, T Spelman, E Havrdova, ...
Brain 139 (9), 2395-2405, 2016
Predictors of long‐term disability accrual in relapse‐onset multiple sclerosis
VG Jokubaitis, T Spelman, T Kalincik, J Lorscheider, E Havrdova, ...
Annals of neurology 80 (1), 89-100, 2016
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis
A He, T Spelman, V Jokubaitis, E Havrdova, D Horakova, M Trojano, ...
JAMA neurology 72 (4), 405-413, 2015
Gas6 deficiency increases oligodendrocyte loss and microglial activation in response to cuprizone-induced demyelination
MD Binder, HS Cate, AL Prieto, D Kemper, H Butzkueven, MM Gresle, ...
Journal of Neuroscience 28 (20), 5195-5206, 2008
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study
T Kalincik, JWL Brown, N Robertson, M Willis, N Scolding, CM Rice, ...
The Lancet Neurology 16 (4), 271-281, 2017
Sex as a determinant of relapse incidence and progressive course of multiple sclerosis
T Kalincik, V Vivek, V Jokubaitis, J Lechner-Scott, M Trojano, G Izquierdo, ...
Brain 136 (12), 3609-3617, 2013
Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis
JWL Brown, A Coles, D Horakova, E Havrdova, G Izquierdo, A Prat, ...
Jama 321 (2), 175-187, 2019
Defining reliable disability outcomes in multiple sclerosis
T Kalincik, G Cutter, T Spelman, V Jokubaitis, E Havrdova, D Horakova, ...
Brain 138 (11), 3287-3298, 2015
Risk of relapse phenotype recurrence in multiple sclerosis
T Kalincik, K Buzzard, V Jokubaitis, M Trojano, P Duquette, G Izquierdo, ...
Multiple Sclerosis Journal 20 (11), 1511-1522, 2014
The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude
J Lechner-Scott, B Spencer, T De Malmanche, J Attia, M FitzGerald, ...
Multiple Sclerosis Journal 18 (7), 974-982, 2012
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility
International Multiple Sclerosis Genetics Consortium*†, ANZgene, ...
Science 365 (6460), eaav7188, 2019
Towards personalized therapy for multiple sclerosis: prediction of individual treatment response
T Kalincik, A Manouchehrinia, L Sobisek, V Jokubaitis, T Spelman, ...
Brain 140 (9), 2426-2443, 2017
Predictors of disability worsening in clinically isolated syndrome
VG Jokubaitis, T Spelman, T Kalincik, G Izquierdo, F Grand'Maison, ...
Annals of clinical and translational neurology 2 (5), 479-491, 2015
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry
S Hughes, T Spelman, M Trojano, A Lugaresi, G Izquierdo, ...
Journal of Neurology, Neurosurgery & Psychiatry 83 (3), 305-310, 2012
The Australian Multiple Sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platform
VG Jokubaitis, T Spelman, J Lechner-Scott, M Barnett, C Shaw, S Vucic, ...
PloS one 8 (3), e59694, 2013
Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome
C Meyniel, T Spelman, VG Jokubaitis, M Trojano, G Izquierdo, ...
PloS one 7 (6), e38661, 2012
Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing–remitting multiple sclerosis
T Kalincik, V Jokubaitis, G Izquierdo, P Duquette, M Girard, P Grammond, ...
Multiple Sclerosis Journal 21 (9), 1159-1171, 2015
The system can't perform the operation now. Try again later.
Articles 1–20